Literature DB >> 24309533

Which donor or graft source should you choose for the strongest GVL? Is there really any difference.

Daniel Weisdorf1.   

Abstract

Patients undergoing allogeneic hematopoietic cell transplantation (HCT) face relapse of their malignancy as the most frequent cause of treatment failure. It has been postulated that the allogeneic neoplastic potency of different donor or graft sources may differ and in some situations, a particular graft source might be preferred. Data on this supposition has been reviewed here to consider HLA-matched siblings, HLA-matched or partially matched unrelated donors (URD), unrelated umbilical cord blood (UCB), and haploidentical as well as blood or marrow grafts.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GVL, graft-versus-leukemia; HCT, hematopoietic cell transplantation; HLA-matched donors; UCB, umbilical cord blood; bone marrow; graft source; haploidentical; peripheral blood; relapse

Mesh：

Substances：

Year:  2013        PMID： 24309533      PMCID： PMC3900021          DOI： 10.1016/j.beha.2013.10.010

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  15 in total

1.  Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia.

Authors:  Mei-Jie Zhang; Stella M Davies; Bruce M Camitta; Brent Logan; Karin Tiedemann; Mary Eapen; Elizabeth L Thiel
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-06       Impact factor: 5.742

2.  Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood.

Authors:  Claudio G Brunstein; Jonathan A Gutman; Daniel J Weisdorf; Ann E Woolfrey; Todd E Defor; Theodore A Gooley; Michael R Verneris; Frederick R Appelbaum; John E Wagner; Colleen Delaney
Journal:  Blood       Date:  2010-08-04       Impact factor: 22.113

3.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age.

Authors:  C Kollman; C W Howe; C Anasetti; J H Antin; S M Davies; A H Filipovich; J Hegland; N Kamani; N A Kernan; R King; V Ratanatharathorn; D Weisdorf; D L Confer
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

4.  Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.

Authors:  Mary Eapen; Vanderson Rocha; Guillermo Sanz; Andromachi Scaradavou; Mei-Jie Zhang; William Arcese; Anne Sirvent; Richard E Champlin; Nelson Chao; Adrian P Gee; Luis Isola; Mary J Laughlin; David I Marks; Samir Nabhan; Annalisa Ruggeri; Robert Soiffer; Mary M Horowitz; Eliane Gluckman; John E Wagner
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316

5.  Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes.

Authors:  Claudio G Brunstein; Mary Eapen; Kwang Woo Ahn; Frederick R Appelbaum; Karen K Ballen; Richard E Champlin; Corey Cutler; Fangyu Kan; Mary J Laughlin; Robert J Soiffer; Daniel J Weisdorf; Anne Woolfrey; John E Wagner
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

6.  Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.

Authors:  Wael Saber; Shaun Opie; J Douglas Rizzo; Mei-Jie Zhang; Mary M Horowitz; Jeff Schriber
Journal:  Blood       Date:  2012-02-10       Impact factor: 22.113

7.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

Authors:  Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

8.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Authors:  Olle Ringdén; Steven Z Pavletic; Claudio Anasetti; A John Barrett; Tao Wang; Dan Wang; Joseph H Antin; Paolo Di Bartolomeo; Brian J Bolwell; Christopher Bredeson; Mitchell S Cairo; Robert P Gale; Vikas Gupta; Theresa Hahn; Gregory A Hale; Jorg Halter; Madan Jagasia; Mark R Litzow; Franco Locatelli; David I Marks; Philip L McCarthy; Morton J Cowan; Effie W Petersdorf; James A Russell; Gary J Schiller; Harry Schouten; Stephen Spellman; Leo F Verdonck; John R Wingard; Mary M Horowitz; Mukta Arora
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

9.  Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units.

Authors:  Michael R Verneris; Claudio G Brunstein; Juliet Barker; Margaret L MacMillan; Todd DeFor; David H McKenna; Michael J Burke; Bruce R Blazar; Jeffrey S Miller; Philip B McGlave; Daniel J Weisdorf; John E Wagner
Journal:  Blood       Date:  2009-08-25       Impact factor: 22.113

10.  HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.

Authors:  Mukta Arora; Daniel J Weisdorf; Stephen R Spellman; Michael D Haagenson; John P Klein; Carolyn K Hurley; George B Selby; Joseph H Antin; Nancy A Kernan; Craig Kollman; Auayporn Nademanee; Philip McGlave; Mary M Horowitz; Effie W Petersdorf
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544
View more
  4 in total

1.  A living band-aid for epidermolysis bullosa.

Authors:  Jakub Tolar; Miroslav Tolar
Journal:  Blood Transfus       Date:  2015-01       Impact factor: 3.443

2.  Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update.

Authors:  W Arcese; A Picardi; S Santarone; G De Angelis; R Cerretti; L Cudillo; E Pennese; P Bavaro; P Olioso; T Dentamaro; L Cupelli; A Chierichini; A Ferrari; A Mengarelli; M C Tirindelli; M Testi; F Di Piazza; P Di Bartolomeo
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

3.  Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient.

Authors:  Satiro N De Oliveira; Roy L Kao; Andrew Pham; LaMarr Taylor Smith; Pamela Kempert; Theodore B Moore
Journal:  Pediatr Transplant       Date:  2016-02-05

4.  Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.

Authors:  Maria H Gilleece; Avichai Shimoni; Myriam Labopin; Stephen Robinson; Dietrich Beelen; Gerard Socié; Ali Unal; Arnold Ganser; Antonin Vitek; Henrik Sengeloev; Ibrahim Yakoub-Agha; Eleni Tholouli; Emmanuelle Polge; Mohamad Mohty; Arnon Nagler
Journal:  Blood Cancer J       Date:  2021-05-12       Impact factor: 11.037
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.